CUV Update - Notification of buy-back - CUV |
18/03/24 | | 13.65KB | Share |
|
CUV Notification of buy-back - CUV |
14/03/24 | | 13.06KB | Share |
|
CUV CLINUVEL initiates on market share buy-back program |
14/03/24 | PRICE SENSITIVE | 89.87KB | Share |
|
CUV New case of SCENESSE efficacy in vitiligo presented at AAD |
11/03/24 | PRICE SENSITIVE | 362.39KB | Share |
|
CUV SCENESSE Presented at American Academy of Dermatology |
08/03/24 | | 74.91KB | Share |
|
CUV Ceasing to be a substantial holder |
05/03/24 | | 1.12MB | Share |
|
CUV SCENESSE provides photoprotection in variegate porphyria |
04/03/24 | PRICE SENSITIVE | 195.58KB | Share |
|
CUV Becoming a substantial holder |
28/02/24 | | 1.69MB | Share |
|
CUV Final Director's Interest Notice |
27/02/24 | | 188.5KB | Share |
|
CUV Half Year Results Webinar Recording |
23/02/24 | | 58.64KB | Share |
|
CUV CLINUVEL Delivers Increased Revenues, Solid Earnings |
22/02/24 | | 107.14KB | Share |
|
CUV CUV Appendix 4D Half Year Report |
22/02/24 | PRICE SENSITIVE | 570.89KB | Share |
|
CUV Director Resignation |
21/02/24 | | 67.94KB | Share |
|
CUV CEO Letter to Shareholders |
16/02/24 | | 103.23KB | Share |
|
CUV Half Year Results Investor Webinar |
16/02/24 | | 59.78KB | Share |
|
CUV Change in substantial holding |
31/01/24 | | 1.58MB | Share |
|
CUV CLINUVEL Newsletter 1 - January 2024 |
16/01/24 | | 256.64KB | Share |
|
CUV Chair Elect Letter |
14/12/23 | | 106.04KB | Share |
|
CUV Change to Registered Office |
07/12/23 | | 129.35KB | Share |
|
CUV Notification of cessation of securities - CUV |
27/11/23 | | 21.49KB | Share |
|
CUV Change of Director's Interest Notice |
27/11/23 | | 526.02KB | Share |
|
CUV Application for quotation of securities - CUV |
27/11/23 | | 25.55KB | Share |
|
CUV CLINUVEL Newsletter V - November 2023 |
24/11/23 | | 481.47KB | Share |
|
CUV Sydney Vitiligo Presentation |
10/11/23 | | 874.94KB | Share |
|
CUV Final Director's Interest Notice |
02/11/23 | | 190.98KB | Share |
|
CUV CLINUVEL Appoints New Chair |
31/10/23 | | 135.75KB | Share |
|
CUV Results of Meeting |
31/10/23 | | 276.04KB | Share |
|
CUV CEO Presentation AGM |
31/10/23 | | 1.94MB | Share |
|
CUV Chair's Address |
31/10/23 | | 160.97KB | Share |
|
CUV CLINUVEL starts global Phase III vitiligo study |
18/10/23 | | 233.67KB | Share |
|
CUV CLINUVEL Newsletter IV - October 2023 |
06/10/23 | | 245.17KB | Share |
|
CUV Board Changes after AGM |
29/09/23 | | 141.26KB | Share |
|
CUV Notice of Annual General Meeting/Proxy Form |
29/09/23 | | 577.45KB | Share |
|
CUV Change of Director's Interest Notice |
20/09/23 | | 321.36KB | Share |
|
CUV CEO Letter to Shareholders |
19/09/23 | | 192.64KB | Share |
|
CUV CLINUVEL Confirms AGM Date |
13/09/23 | | 117.29KB | Share |
|
CUV CLINUVEL Vitiligo Expert Panel |
12/09/23 | | 217.38KB | Share |
|
CUV SCENESSE in Adolescent EPP Study |
05/09/23 | | 228.91KB | Share |
|
CUV CLINUVEL Investor Webinar Transcript |
30/08/23 | | 895.6KB | Share |
|
CUV Appendix 4G and Corporate Governance Statement |
29/08/23 | | 579.18KB | Share |
|
CUV CLINUVEL delivering increases in annual revenue, profit |
29/08/23 | | 271.69KB | Share |
|
CUV Dividend/Distribution - CUV |
29/08/23 | | 22.38KB | Share |
|
CUV Appendix 4E and Annual Report to Shareholders 2023 |
29/08/23 | PRICE SENSITIVE | 12.68MB | Share |
|
CUV Annual Results Investor Webinar - time |
28/08/23 | | 131.05KB | Share |
|
CUV Technical Note - CUV151 results DNA Damage |
15/08/23 | | 365.52KB | Share |
|
CUV afamelanotide reduces DNA damage in healthy population |
15/08/23 | | 203.48KB | Share |
|
CUV SCENESSE applied under 5 year US Veterans Affairs contract |
26/07/23 | | 140.08KB | Share |
|
CUV CLINUVEL secures IP for melanocortins to treat CNS disorders |
14/07/23 | | 641.45KB | Share |
|
CUV Notification regarding unquoted securities - CUV |
30/06/23 | | 25.38KB | Share |
|
CUV Two Grounds of Appeal Upheld by NICE Panel |
30/06/23 | | 112.15KB | Share |
|
CUV Notification of cessation of securities - CUV |
29/06/23 | | 21.48KB | Share |
|
CUV Presentation - Melbourne Twilight Briefing |
29/06/23 | | 1.08MB | Share |
|
CUV Change of Director's Interest Notice |
28/06/23 | | 313.22KB | Share |
|
CUV CLINUVEL Newsletter III - June 2023 |
26/06/23 | | 303.33KB | Share |
|
CUV Strategic Update VI |
01/06/23 | | 1.84MB | Share |
|
CUV PRENUMBRA administered to moderate & severe stroke patients |
09/05/23 | | 165.07KB | Share |
|
CUV Expansion of global porphyria programs |
01/05/23 | | 136.22KB | Share |
|
CUV CLINUVEL Newsletter II - April 2023 |
05/04/23 | | 425.3KB | Share |
|
CUV Investor Presentation - NYC Nasdaq Event |
30/03/23 | | 4.12MB | Share |
|
CUV Technical Note - CUV803 Study and AIS |
20/03/23 | | 444.01KB | Share |
|
CUV First stroke patient treated with PRENUMBRA Instant |
20/03/23 | | 271.53KB | Share |
|
CUV DNA Repair data presented at AAD Meeting |
17/03/23 | | 119.77KB | Share |
|
CUV Statement on Silicon Valley Bank |
13/03/23 | | 89.95KB | Share |
|
CUV Proposed issue of securities - CUV |
10/03/23 | | 24.54KB | Share |
|
CUV Commercial Update SCENESSE |
09/03/23 | | 127.84KB | Share |
|
CUV Relief from Quarterly Reporting |
02/03/23 | | 82.33KB | Share |
|
CUV CLINUVEL launches first dermatocosmetic product |
01/03/23 | | 254.92KB | Share |
|
CUV Proposed issue of securities - CUV |
28/02/23 | | 24.53KB | Share |
|
CUV Global SCENESSE demand drives increased revenues, earnings |
24/02/23 | | 165.94KB | Share |
|
CUV CUV Appendix 4D Half Year Report |
24/02/23 | PRICE SENSITIVE | 874.85KB | Share |
|
CUV PRENUMBRA formulation completed for clinical trial use |
15/02/23 | | 257.84KB | Share |
|
CUV Chair's Letter |
09/02/23 | | 215.25KB | Share |
|
CUV Technical note - CUV151 results |
02/02/23 | | 370.66KB | Share |
|
CUV Afamelanotide reduces UV skin damage in a healthy population |
02/02/23 | | 168.07KB | Share |
|
CUV Quarterly Activities/Appendix 4C Cash Flow Report |
31/01/23 | PRICE SENSITIVE | 229.38KB | Share |
|
CUV NEURACTHEL manufacturing processes advance |
23/01/23 | | 359.1KB | Share |
|
CUV Technical Note - Xeroderma Pigmentosum |
16/01/23 | | 609.83KB | Share |
|
CUV afamelanotide Reduces DNA Photodamage in XP |
16/01/23 | | 333.77KB | Share |
|
CUV CLINUVEL Newsletter I - January 2023 |
10/01/23 | | 510.39KB | Share |
|
CUV CLINUVEL Newsletter VI - December 2022 |
23/12/22 | | 246.06KB | Share |
|
CUV Notification of cessation of securities - CUV |
21/12/22 | | 21.48KB | Share |
|
CUV Presentation - Jefferies London Healthcare Conference |
17/11/22 | | 3.31MB | Share |
|
CUV CLINUVEL Newsletter V - November 2022 |
09/11/22 | | 546.94KB | Share |
|
CUV Change of Director's Interest Notice |
07/11/22 | | 216.26KB | Share |
|
CUV Quarterly Activities/Appendix 4C Cash Flow Report Re-issued |
31/10/22 | PRICE SENSITIVE | 348.75KB | Share |
|
CUV Quarterly Activities/Appendix 4C Cash Flow Report |
31/10/22 | PRICE SENSITIVE | 347.86KB | Share |
|
CUV Results of Meeting |
26/10/22 | | 144.34KB | Share |
|
CUV Chair Address |
26/10/22 | | 321.32KB | Share |
|
CUV Melbourne Investor Briefing Presentation |
21/10/22 | | 2.68MB | Share |
|
CUV First vitiligo patient enrolled in monotherapy study |
20/10/22 | | 151.05KB | Share |
|
CUV Investor Presentation - Sydney |
14/10/22 | | 3.31MB | Share |
|
CUV Notice of Annual General Meeting/Proxy Form |
23/09/22 | | 3.86MB | Share |
|
CUV Strategic Update V |
19/09/22 | | 408.93KB | Share |
|
CUV Presentation - HC Wainright Global Investment Conference |
13/09/22 | | 869KB | Share |
|
CUV Annual General Meeting Date |
08/09/22 | | 391.42KB | Share |
|
CUV CLINUVEL submits label expansion for adolescent EPP patients |
05/09/22 | | 157.73KB | Share |
|
CUV S&P DJI Announces September 2022 Quarterly Rebalance |
02/09/22 | PRICE SENSITIVE | 134KB | Share |
|
CUV CLINUVEL Investor Webinar Financial Results 2022 |
31/08/22 | | 2.1MB | Share |
|
CUV Appendix 4G and Corporate Governance Statement |
30/08/22 | | 2.57MB | Share |
|
CUV Revenue Growth Drives CLINUVEL's Full Year Profit |
30/08/22 | | 309.29KB | Share |